|
J Biol Chem, Vol. 275, Issue 14, 10673-10682, April 7, 2000
Stimulation of Integrin-mediated Cell Contractility by
Fibronectin Polymerization*
Denise C.
Hocking §,
Jane
Sottile¶, and
Kurt J.
Langenbach¶
From the Department of Pharmacology and Physiology,
University of Rochester Medical Center, Rochester, New York 14642 and
the ¶ Department of Physiology and Cell Biology, Albany Medical
College, Albany, New York 12208
 |
ABSTRACT |
Ligation of integrins with extracellular matrix
molecules induces the clustering of actin and actin-binding proteins to
focal adhesions, which serves to mechanically couple the matrix with the cytoskeleton. During wound healing and development, matrix deposition and remodeling may impart additional tensile forces that
modulate integrin-mediated cell functions, including cell migration and
proliferation. We have utilized the ability of cells to contract
floating collagen gels to determine the effect of fibronectin
polymerization on mechanical tension generation by cells. Our data
indicate that fibronectin polymerization promotes cell spreading in
collagen gels and stimulates cell contractility by a
Rho-dependent mechanism. Fibronectin-stimulated
contractility was dependent on integrin ligation; however, integrin
ligation by fibronectin fragments was not sufficient to induce either
tension generation or cell spreading. Furthermore, treatment of cells with polyvalent RGD peptides or pre-polymerized fibronectin did not
stimulate cell contractility. Fibronectin-induced contractility was
blocked by agents that inhibit fibronectin polymerization, suggesting
that the process of fibronectin polymerization is critical in
triggering cytoskeletal tension generation. These data indicate that
Rho-mediated cell contractility is regulated by the process of
fibronectin polymerization and suggest a novel mechanism by which
extracellular matrix fibronectin regulates cytoskeletal organization
and cell function.
 |
INTRODUCTION |
Fibronectin is a high molecular mass, multidomain glycoprotein
that circulates in a soluble form in the plasma and is also found in an
insoluble, multimeric form within the extracellular matrix (1). The
polymerization of soluble fibronectin into insoluble fibrils within the
extracellular matrix is a dynamic, cell-dependent process
that is mediated by a series of events involving the actin cytoskeleton
and integrin receptors (2). The adhesion of cells to fibronectin via
integrin receptors has been shown to be important in the regulation and
coordination of such complex processes as cell growth, differentiation,
and migration (1). Ligation of integrins with extracellular matrix molecules, including fibronectin, induces the clustering of actin and
actin-binding proteins to focal adhesions, which serves to mechanically
couple the extracellular matrix with the actin cytoskeleton (3). Recent
studies suggest that the interaction of cells with the extracellular
matrix form of fibronectin triggers changes in cell cycle progression
(4-7), cell migration (8), and actin filament organization (6, 9) that
are distinct from those generated by the interaction of cells with
nonpolymerized fibronectin. The mechanism by which the matrix form of
fibronectin gives rise to cellular phenotypes distinct from protomeric
fibronectin is unknown.
Studies aimed at understanding the effect of extracellular matrix on
cell function indicate that cells respond to fibronectin-coated beads
with a local reinforcement of cytoskeletal links that are proportional
to the strength of the force on the integrin (10). Similarly,
cytoskeletal stiffness has been shown to increase in proportion to the
stress applied to integrin receptors (11). Other studies suggest that
cell spreading and migration (12) as well as cytoskeletal assembly (13)
are regulated by the mechanical stiffness of the adhesive substrate.
Taken together, these data suggest a model in which extracellular
matrix fibronectin modulates cell function through local alterations in
cytoskeletal organization that are mediated in part by changes in the
rigidity of the insoluble fibronectin matrix. The cell-mediated
polymerization of soluble fibronectin into an insoluble extracellular
matrix is a tightly controlled process that can be rapidly up- or
down-regulated (14-17). As such, the process of polymerizing an
insoluble fibronectin matrix may serve as a distinct control mechanism
by which the organization of the actin cytoskeleton remains tightly
coupled to the organization of the extracellular environment.
The present study was undertaken to determine whether the
polymerization of fibronectin into an insoluble extracellular matrix specifically influences the organization of the actin cytoskeleton by
strengthening the linkage between the integrin and the cytoskeleton. Tension generation due to increases in cytoskeletal contractility may
be determined directly by imbedding cells into three-dimensional, floating collagen gels and measuring the degree of gel contraction over
time (18). In this well-characterized model of wound contraction, cells
anchored in the collagen matrix organize and contract collagen fibrils
(19-21) by an integrin-dependent mechanism (22-24). To
determine the role of fibronectin deposition on actin organization and
mechanical tension generation, fibronectin-null cells were imbedded
into floating, native type I collagen matrices and the ability of
fibronectin polymerization to stimulate cell spreading and
integrin-mediated collagen gel contraction was assessed. Our data
indicate that fibronectin polymerization stimulates cell spreading
within collagen matrices and triggers a significant increase in
cytoskeletal contractility. The increase in contractility induced by
fibronectin was dependent on integrin ligation; however,
integrin-binding fragments of fibronectin were not sufficient to induce
either tension generation or cell spreading. Fibronectin-induced
contractility was inhibited by agents that inhibit fibronectin
polymerization, suggesting that the process of fibronectin
polymerization is critical in triggering cytoskeletal tension
generation. In addition, fibronectin-induced contractility was
inhibited by pretreatment of cells with C3 exotransferase, suggesting a
role for RhoA in the contractile response of cells to fibronectin
polymerization. Taken together, these data suggest that the
polymerization of a fibronectin matrix triggers integrin-mediated cytoskeletal reorganization and enhanced cell contractility through a
mechanism involving the activation of RhoA.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
Gel electrophoresis supplies were from Bio-Rad.
Lipofectin, GRGDSP, and GRGESP peptides were obtained from Life
Technologies Inc. Laminin (purified from Engelbreth-Holm-Swarm tumors)
and type I rat tail collagen were purchased from Upstate Biotechnology (Lake Placid, NY). Vitronectin was purified from fibronectin- and
fibrinogen-depleted human plasma as described previously (25). Pertussis toxin was obtained from Calbiochem. C3 exoenzyme was obtained
from List Biological Laboratories (Campbell, CA). Unless otherwise
indicated, chemical reagents were obtained from Sigma.
Cell Culture--
Mouse embryo cells, derived from
fibronectin-null embryos and adapted to grow under serum-free
conditions (4), were cultured on collagen-coated dishes in a 1:1
mixture of Cellgro (Mediatech, Herndon, VA) and Aim V (Life
Technologies). These media do not require serum supplementation. Thus,
the fibronectin-null cells were cultured under conditions where no
exogenous source of fibronectin or other extracellular matrix protein
is present.
Purification of Fibronectin and Fibronectin Fragments--
Human
plasma fibronectin was isolated from Cohn's fraction I and II (a gift
of Dr. Kenneth Ingham, American Red Cross, Rockville, MD) essentially
as described previously (26). Figure 1
shows a schematic diagram of the various fibronectin fragments used in
this study. The 70-kDa amino-terminal fragment of fibronectin was
generated by limited digestion with cathepsin D, followed by gelatin
affinity chromatography, as described previously (27). To cleave the
70-kDa fragment into the 27-kDa heparin-binding and 40-kDa
gelatin-binding fragments, the 70-kDa fragment was digested with
trypsin, as described (28). The 40-kDa gelatin-binding fragment was
isolated from the 27-kDa fragment by retention on gelatin affinity
columns (28). The 60-kDa gelatin-binding fragment was prepared by
limited digestion of fibronectin with human leukocyte elastase and
purified by retention on gelatin-Sepharose followed by anion exchange
on DEAE-Sephacel (Amersham Pharmacia Biotech), as described (29). The
120-kDa cell-binding fragment was prepared by digestion of fibronectin
with chymotrypsin and was isolated from the unbound fractions of
sequential gelatin- and heparin-Sepharose affinity columns, as
described (30). The 160/180-kDa cell- and gelatin-binding fragments
were generated by limited digestion with trypsin and isolated by
retention on gelatin-Sepharose, as described (27). Purity of fragments
was assessed by SDS-PAGE1 and
fragments were frozen at 80 °C until use.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
Fibronectin fragments. Schematic
representation of the fibronectin molecule illustrating relative
positions of proteolytically derived fibronectin fragments. Shown are
the 27-kDa (cathepsin-trypsin: amino-terminal), 40-kDa
(cathepsin-trypsin: gelatin-binding), 60-kDa (elastase:
gelatin-binding), 70-kDa (cathepsin: amino-terminal), 120-kDa
(chymotrypsin: cell-binding), and 160/180-kDa (trypsin: gelatin- and
cell-binding) fragments. Rectangles, type I modules;
ovals, type II modules; squares, type III
modules; stippled square, III-10.
|
|
Preparation of Recombinant Fibronectins--
A fragment from the
first type III repeat of fibronectin, III-1C, was produced as a
recombinant fusion protein containing six histidine residues at the
carboxyl terminus, as described previously (8). Briefly, polymerase
chain reaction (PCR) (31) was used to amplify human fibronectin
cDNA (a gift of Dr. Jean Thiery, Institut Curie, Paris, France)
encoding amino acids 600-674. Amino acids were numbered from the
amino-terminal pyroglutamic acid (32). The primers used for
amplification have been described previously (8). The PCR product was
cloned into the bacterial expression vector, pQE-12 (Qiagen, Santa
Clarita, CA). PCR-amplified DNA was sequenced to ensure that no base
changes had been introduced during amplification. III-1C was expressed
in M15 bacteria and purified on Ni-NTA resin (Qiagen) according to the
manufacturer's instructions.
Full length rat fibronectin cDNA and a 3' cDNA clone in which
the coding sequence for the RGD site was deleted (33) were generous
gifts of Dr. Jean Schwarzbauer (Princeton University, Princeton, NJ).
Full length fibronectin cDNA lacking the coding sequence for the
RGD site was generated by ligating an RsrII-XbaI fragment from the RGD fibronectin with wild type fibronectin cDNA from which the corresponding RsrII-XbaI
fragment was removed. The resulting cDNA encodes for full length
fibronectin lacking the RGD site. Recombinant wild type and RGD
fibronectin were expressed in insect cells using a baculovirus
expression system essentially as described (34). Insect cells were
infected with recombinant viruses, and conditioned medium was collected
44 h after infection. Insect cells do not produce detectable
fibronectin and were maintained in defined media (SF-900-II, Life
Technologies) lacking serum supplementation. Thus, recombinant
fibronectins were produced under conditions where no nonrecombinant
source of fibronectin was present. Purity of III1-C and recombinant
fibronectins was assessed by SDS-PAGE, and aliquots were stored at
80 °C before use.
Antibodies--
9D2 hybridoma cells were a gift from Dr. Deane
Mosher (University of Wisconsin, Madison, WI). The epitope recognized
by 9D2 is found within the III-1 module of fibronectin (35). Ascites was generated by TSD Bioservices (Newark, DE). Immunoglobulins (IgGs)
and Fab' fragments were purified as described previously (36).
Nonimmune mouse F(ab')2 fragments (Cappel, Durham, NC) were
similarly reduced, alkylated, and dialyzed against PBS to produce Fab'
fragments. Purity was assessed by SDS-PAGE and aliquots were stored at
80 °C prior to use.
Anti-integrin 1 (Ha2/5), 1 (Ha31/8),
2 (Hma2), 5 (5H10-27), and
v (H9.2B8) subunit antibodies were obtained from
Pharmingen (San Diego, CA). Antibodies directed against the
gelatin-binding domain (IST-10) and III-5 module (IST-5) of fibronectin
were obtained from Chemicon International (Temecula, CA). The
anti-fibronectin polycolonal antibody was purchased from Sigma.
Purified hamster IgM, hamster IgG, and rat IgG2a were purchased from Pharmingen.
Collagen Gel Contraction Assays--
Fibronectin-null cells were
harvested from monolayer culture by treatment with 0.08% trypsin (Life
Technologies) and 0.5 mM EDTA. Trypsin activity was
neutralized with an equal volume of 10 mg/ml soybean trypsin inhibitor.
Cells were washed one time with 1 mg/ml soybean trypsin inhibitor in
PBS and then resuspended in a 1:1 mixture of Cellgro/AimV.
Native type I collagen gels were prepared by mixing collagen, 0.1 N NaOH, 2× concentrated Dulbecco's modified Eagle's
medium (DMEM; Life Technologies) and 1× DMEM on ice such that the
final mixture contained 0.8 mg/ml collagen and 1× DMEM (37).
Fibronectin-null cells were added to the neutralized type I collagen
solutions at 2 × 105 cell/ml. Control wells (no
cells) received an equal volume of media alone. Fibronectin and
fragments were added to the collagen solutions prior to the addition of
cells. To form prepolymerized fibronectin, 20 nM soluble
fibronectin was incubated for 30 min at 20 °C with 62.5 µM III-1C (8) prior to its addition to the collagen
solution. Control cells were incubated with either 20 nM
fibronectin or 62.5 µM III-1C incubated under identical
conditions. In some experiments, aliquots of cells were incubated with
anti-integrin antibodies for 30 min prior to their addition to the
collagen solution. To form floating gels, aliquots (0.1 ml/well) of the collagen/cell mixtures were added to wells of 96-well tissue culture plates (Corning/Costar, Corning, NY) precoated with 2% BSA. The collagen/cell mixtures were allowed to polymerize for 1 h at
37 °C in 8% CO2. Following this incubation,100 µl of
Cellgro/Aim V was added to wells and the edges of the wells were scored
to ensure that the gels were not attached to the wells. In experiments not shown, DMEM was substituted for Cellgro/AimV and similar levels of
contraction were observed.
To determine the extent of contraction, gels were incubated for various
periods of time at 37 °C in 8% CO2 and then removed from the wells and weighed. Collagen gel contraction was measured as a
decrease in gel weight, using a Mettler AE260 balance with a
sensitivity of 0.1 mg (37, 38). Data are reported as a percentage of
the weight of polymerized gels not containing cells (original gel
weight); the weight of polymerized collagen gels without cells was
typically 50 mg. Each datum point was calculated as the mean ± S.E. of quadruplicate samples. All experiments were performed at least
two or more times. Statistical comparison between experimental conditions was performed using the Student's t test for
unpaired samples. Differences described as significant in the text are p < 0.01, unless otherwise indicated.
Fibronectin polymerization by fibronectin-null cells was determined by
imbedding cells in collagen gels in the presence of 40 nM
fibronectin, in the absence and presence of 50 µg/ml 9D2 IgG (35) or
nonimmune mouse IgG. Following a 24-h incubation, gels were removed
from the wells and added directly to 2× SDS-PAGE gel buffer (final
concentration: 4% SDS and 20% glycerol in 0.05 M Tris, pH
6.8). Some samples were reduced with 2% -mercaptoethanol. Samples
were analyzed by SDS-PAGE and immunoblotting, as described previously
(39).
Pertussis Toxin and C3 Exotransferase Pretreatment--
To
pretreat cells with pertussis toxin, monolayer cultures of
fibronectin-null cells were washed 2× with DMEM and incubated overnight with 25 ng/ml pertussis toxin diluted in DMEM (40). Control
cells were incubated with DMEM alone. Cells were then harvested as
indicated above. To pretreat cells with C3 exotransferase, Lipofectin
was used as a delivery vehicle (40, 41). C3 exotransferase and
Lipofectin were diluted in DMEM, incubated for 1 h at 20 °C, and then diluted with additional DMEM to give a final concentration of
2 µg/ml C3 exotransferase and 10 µg/ml Lipofectin. Fibronectin-null cells that had grown to 70% confluence in a monolayer were washed 2×
with DMEM and incubated overnight at 37 °C with either C3
exotransferase/Lipofectin, Lipofectin alone, or DMEM. Following this
incubation, the media was removed and cells were incubated an
additional 1 h with Cellgro/AimV. Cells were then harvested as
indicated above.
Immunofluorescence Microscopy--
Fibronectin-null cells
imbedded in collagen gels were fixed with 4% paraformaldehyde in
Small's cytoskeletal buffer (42) for 1 h at 20 °C, rinsed
several times with Small's buffer, and then permeabilized for 5 min at
20 °C with ice-cold acetone. Gels were washed 3× with Small's
buffer, blocked with 10 mg/ml glycine and 1% BSA, and then stained for
actin using FITC-phalloidin (Molecular Probes, Eugene, OR). Gels were
mounted in o-phenylenediamine, examined using an Olympus
BX60 microscope equipped with epifluorescence, and photographed using a
digital camera (Spot, Diagnostic Instruments, Sterling Heights, MI).
 |
RESULTS |
Fibronectin Induces Contraction of Floating Type I Collagen
Gels--
To determine the effect of fibronectin on cytoskeletal
tension generation, fibronectin-null cells were imbedded in floating collagen matrices in the absence and presence of increasing
concentrations of intact fibronectin. Most adherent cells, including
fibroblasts and endothelial cells, continually produce an extensive
endogenous fibronectin matrix. Fibronectin-null cells do not produce
any detectable fibronectin but are capable of assembling a fibronectin matrix when cultured in the presence of exogenously added fibronectin (4). Thus, in this system, the levels of extracellular matrix fibronectin can be precisely manipulated in order to determine the
exact role of fibronectin polymerization on cytoskeletal organization. In the absence of fibronectin, fibronectin-null cells imbedded in
collagen gels retained approximately 75-50% of the original gel
weight. This corresponds to basal levels of contraction of between
25-50% (Figs. 2-4 and 6-11).
Coincubation of fibronectin-null cells with plasma fibronectin
triggered a further, dose-dependent decrease in gel weight
(Fig. 2A); the addition of 80 nM of fibronectin (40 µg/ml) to collagen-imbedded cells resulted in an 83.9 ± 1.6% decrease in gel weight (Fig. 2A). The decrease in gel
weight that occurs as a result of fluid extrusion has previously been
shown to parallel the extent of collagen gel contraction (37, 38). Similar results were also obtained by measuring the diameter of contracted gels (data not shown). A similar, significant decrease in
collagen gel weight was also observed following addition of fibronectin
to human embryonic dermal fibroblasts (data not shown). These data
indicate that the interaction of cells with fibronectin stimulates cell contraction.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of fibronectin on collagen gel
contraction. Fibronectin-null cells (2 × 105
cell/ml) were mixed with neutralized type I collagen (0.8 mg/ml) on ice
in the absence and presence of increasing concentrations of fibronectin
(A) or a 40-nM concentration of either
fibronectin (Fn), vitronectin (Vn), or laminin
(Ln) or an equal volume of PBS (B). Cell/collagen
mixtures were added to BSA-coated tissue culture wells and allowed to
polymerize at 37 °C for 1 h after which time serum-free media
was added. Gels were incubated an additional 20 h at 37 °C and
then weighed. Data are presented as a percentage of the weight of gels
not containing cells ± S.E.
|
|
To determine whether this stimulation of cell contractility is a
property specific to fibronectin, the effect of other extracellular matrix molecules on cell-mediated collagen gel contraction was assessed. As demonstrated in Fig. 2B, coincubation of cells
with equal molar concentrations of either vitronectin or laminin had no
effect on collagen gel weight. These data suggest that stimulation of
cell contractility is not a general property of extracellular matrix molecules.
Time Course of Fibronectin-induced Contraction--
Previous
studies indicate that treatment of fibroblasts with either
lysophosphatidic acid (LPA) or platelet-derived growth factor results
in a steady increase in the contraction of floating collagen gels when
measured over a period of 4 h (40). Others studies have
demonstrated that cells imbedded in attached collagen gels undergo a
rapid contraction within the first 10 min of release followed by a
slower contraction that continues for 3-4 days (13). To determine the
rate at which fibronectin stimulates collagen gel contraction,
fibronectin-null cells were imbedded in collagen gels in the absence
and presence of 40 nM plasma-derived or recombinant fibronectin. As demonstrated in Fig. 3,
differences in collagen gel weight between the control and
fibronectin-treated cells became apparent between 4 and 6 h after
initial gel polymerization. Fibronectin-stimulated contraction
continued to increase over a 20-h period (Fig. 3). In addition,
plasma-derived or recombinant fibronectin stimulated contraction at
similar rates (Fig. 3). Recombinant fibronectin was produced in insect
cells grown in the absence of serum and, therefore, provides evidence
that the fibronectin-induced collagen gel contraction is not due to the
contamination of plasma-derived fibronectin with growth factors.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 3.
Time course of fibronectin-induced collagen
gel contraction. Fibronectin-null cells were imbedded into
collagen gels as indicated in the legend to Fig. 2, in the absence
( Fn, ) or presence of 40 nM plasma-derived
(+pFn, ) or recombinant (+rFn, )
fibronectin. Gels were allowed to polymerize at 37 °C for 1 h
after which time serum-free media was added to the wells. At various
times, separate gels were removed and weighed. Data are presented as a
percentage of the weight of gels not containing cells ± S.E.
|
|
Effect of Fibronectin Fragments on Collagen Gel
Contraction--
Fibronectin contains multiple binding sites,
including those for sulfated glycosaminoglycans, collagen or gelatin,
fibrin, cell surface integrin receptors, and fibronectin matrix
assembly receptors (1). Ligation of integrin receptors by fragments of
fibronectin has been shown to cause changes in both actin cytoskeleton organization and intracellular signaling (3, 43-45). Additional studies indicate that the interaction of cells with the
carboxyl-terminal heparin-binding domain of fibronectin in conjunction
with integrin receptor ligation enhances actin stress fiber formation
(46, 47). To determine whether the contraction-promoting effect of fibronectin could be localized to either integrin- and/or
heparin-binding regions of fibronectin, fibronectin-null cells were
imbedded in collagen gels in the presence of various proteolytic
fragments of fibronectin. The extent of collagen gel contraction in the presence of 40 nM intact fibronectin was compared with that
observed when cells were incubated with equal molar concentrations of
any of the 27-kDa (matrix assembly, heparin-binding), 40-kDa
(gelatin-binding), 60-kDa (gelatin-binding), 70-kDa (matrix assembly,
gelatin-binding),120-kDa (integrin-binding), or 160/180-kDa (integrin-
and heparin-binding) fibronectin fragments (see Fig. 1). As shown in
Fig. 4, incubation of collagen-imbedded
fibronectin-null cells with fibronectin fragments had no effect on
collagen gel contraction. Moreover, simultaneous incubation of cells
with two fibronectin fragments that together encompass the entire
fibronectin molecule (160/180- and 27-kDa fragments) did not stimulate
collagen gel contraction. These data suggest that the interaction of
cells with either integrin- and/or heparin-binding fragments of
fibronectin is not sufficient to stimulate contractility of cells
imbedded in collagen matrices.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of fibronectin fragments on collagen
gel contraction. Fibronectin-null cells were imbedded into
collagen gels as indicated in the legend to Fig. 2. At the time of
seeding, a 40-nM concentration of either intact fibronectin
(+Fn) or various fibronectin fragments encompassing the
entire fibronectin molecule were added to the collagen/cell mixture.
Collagen gels were cast and processed as indicated in the legend to
Fig. 2. Data are presented as a percentage of the weight of gels not
containing cells ± S.E.
|
|
Fibronectin Polymerization Is Required for Fibronectin-mediated
Contraction--
Upon binding to cells, fibronectin accumulates as
high molecular mass multimers that do not penetrate the stacking gel
when analyzed by SDS-PAGE. These multimers, which are thought to
represent fibronectin in the extracellular matrix, can be dissociated
to monomeric fibronectin with reducing agents (48). In addition, previous studies have demonstrated that polymerization of a fibronectin matrix by fibroblast (35) or fibronectin-null cell (4) monolayers is
inhibited by the addition of the anti-fibronectin III-1 monoclonal antibody, 9D2. To characterize the ability of fibronectin-null cells to
polymerize fibronectin within a collagen lattice, fibronectin-null cells were imbedded in floating collagen gels in the presence of 40 nM fibronectin, in the absence and presence of either 50 µg/ml 9D2 IgG or nonimmune mouse IgG. Following a 24-h incubation, the collagen gels were solubilized with gel buffer and analyzed by
immunoblotting using a polyclonal anti-fibronectin antibody. As
demonstrated in Fig. 5, addition of
fibronectin to cells imbedded in collagen gels results in the formation
of high molecular mass aggregates that do not penetrate the stacking
gel. In the presence of a reducing agent, no high molecular mass
aggregates were detected (Fig. 5). Furthermore, addition of the 9D2 mAb
to fibronectin-treated cells inhibited the formation of these high
molecular mass fibronectin aggregates. In contrast, addition of an
equal concentration of nonimmune IgG to fibronectin-treated cells had
no effect on fibronectin multimer formation (Fig. 5). These data
indicate that fibronectin-null cells imbedded within a collagen lattice
can polymerize fibronectin into high molecular mass multimers by a
process that can be inhibited by the anti-fibronectin antibody,
9D2.

View larger version (73K):
[in this window]
[in a new window]
|
Fig. 5.
Fibronectin polymerization by
collagen-imbedded cells. Fibronectin-null cells were imbedded into
collagen gels as indicated in the legend to Fig. 2, in the presence of
40 nM intact fibronectin. At the time of seeding, cells
were either left untreated (A) or incubated with 50 µg/ml
9D2 mAb (B) or nonimmune mouse IgG (C).
Fibronectin was visualized by SDS-PAGE under nonreducing and reducing
conditions followed by immunoblotting with a polyclonal
anti-fibronectin antibody. The fibronectin starting material
(SM) is shown. The positions of multimeric (HMW),
dimeric (D), and monomeric (M) fibronectin are
indicated.
|
|
The fibronectin fragments assayed for their ability to increase cell
contractility (Fig. 4) contain binding sites for cell surface receptors
(32, 49) but do not become incorporated into the high molecular mass
multimers typically observed in the extracellular matrix (27). To
determine whether the ability of fibronectin to stimulate cell
contractility depends on its incorporation into insoluble fibrils, the
effect of inhibitors of fibronectin polymerization on
fibronectin-induced collagen gel contraction was assessed.
Fibronectin-null cells were imbedded in collagen gels in the presence
of 40 nM fibronectin, and in the absence and presence of
either 9D2 Fab' fragments (Fig.
6A) or 70-kDa amino-terminal
fibronectin fragments (27, 50) (Fig. 6B). Addition of either
9D2 Fab' fragments (Fig. 6A) or 70-kDa fibronectin fragments
(Fig. 6B) to collagen-imbedded fibronectin-null cells
resulted in a dose-dependent inhibition of
fibronectin-mediated collagen gel contraction. In contrast, addition of
either nonimmune mouse Fab' (Fig. 6A) or the nonblocking
40-kDa fibronectin fragment (Fig. 6B) had no effect on the
fibronectin-induced decrease in collagen gel weight. Taken together,
these data suggest that fibronectin polymerization is essential for the
development of fibronectin-mediated contraction.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Role of fibronectin polymerization in
collagen gel contraction. Fibronectin-null cells were imbedded
into collagen gels as indicated in the legend to Fig. 2, in the absence
or presence of 40 nM intact fibronectin (Fn). In
A, increasing concentrations of the anti-FnIII-1 antibody,
9D2, or 25 µg/ml nonimmune Fab' fragments (mFab') were
added to the cell/collagen mixtures. In B, increasing
concentrations of the 70-kDa fibronectin fragment or an equal molar
concentration of the control 40-kDa fibronectin fragment were added to
the cell/collagen mixtures. Collagen gels were cast and processed as
indicated in the legend to Fig. 2. Data are presented as a percentage
of the weight of gels not containing cells ± S.E.
|
|
Integrin Ligation Is Required but Not Sufficient for
Fibronectin-mediated Collagen Gel Contraction--
Our data using
integrin-binding fragments of fibronectin suggest that
fibronectin-integrin ligation is not sufficient to trigger an increase
in cell contractility. To determine whether Arg-Gly-Asp (RGD)-mediated
integrin ligation is required for fibronectin-mediated tension
generation, fibronectin-null cells were imbedded in collagen gels in
the absence and presence of a recombinant fibronectin in which the RGD
sequence had been deleted. As shown previously in Fig. 3, treatment of
collagen-imbedded cells with either plasma-derived or recombinant, wild
type fibronectin resulted in a significant decrease in collagen gel
weight (Fig. 7). Deletion of the
integrin-binding RGD repeat from fibronectin abolished the ability of
fibronectin to induce collagen gel contraction (Fig. 7). Furthermore,
addition of 850 µM RGD peptides to plasma
fibronectin-treated cells completely inhibited the contractile response
of cells to fibronectin (Fig. 7). Fibronectin-induced contraction was
similarly inhibited by the addition of a 0.7-µM
concentration of the larger, 120-kDa fibronectin fragment (data not
shown). In contrast, addition of the inactive peptide, RGE (30), had no
effect on fibronectin-induced contraction (Fig. 7). Cell adhesion to
native collagen fibrils is RGD-independent (51, 52). Hence, the
addition of RGD fragments to fibronectin-treated cells did not affect
the 35% decrease in collagen gel weight that occurred independently of
fibronectin (Fig. 7). Taken together, these data indicate that
fibronectin-integrin ligation is required, but not sufficient, to
induce increased cell contractility.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Role of fibronectin's integrin-binding RGD
repeat in collagen gel contraction. Fibronectin-null cells were
imbedded in collagen gels as indicated in the legend to Fig. 2, in the
absence (+0) or presence of 40 nM plasma
fibronectin (pFn), recombinant wild type fibronectin
(rFn), or a recombinant fibronectin lacking the RGD sequence
(rFn RGD). In other wells, cells were incubated with 40 nM plasma fibronectin in the presence of 0.5 mg/ml (850 µM) GRGDSP (RGD) or GRGESP (RGE)
peptides. Collagen gels were cast and processed as indicated in the
legend to Fig. 2. Data are presented as a percentage of the weight of
gels not containing cells ± S.E.
|
|
The adhesion of nonactivated lymphocytes is stimulated upon interaction
with either a polymeric construct of RGD repeats or prepolymerized
fibronectin, but it does not occur upon interaction with the 120-kDa
integrin-binding fibronectin fragment (53). These data suggest that the
number or spatial organization of integrin-binding sites may be
critical in initiating a cellular response to fibronectin. To determine
whether cell contractility can be stimulated by polyvalent
integrin-binding fragments, fibronectin-null cells were imbedded into
collagen gels in the absence and presence of either intact fibronectin,
monomeric RGD peptides, or polymeric RGD peptides. Concentrations of
proteins used were adjusted to reflect an equal molar concentration of
RGD repeats. Treatment of cells with monomeric or polymeric RGD
repeats, or with a 1000-fold excess of monomeric or polymeric RGD
repeats versus 40 nM fibronectin, did not
stimulate collagen gel contraction (Fig.
8A).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of polyvalent fibronectin substrates
on collagen gel contraction. Fibronectin-null cells were imbedded
into collagen gels as indicated in the legend to Fig. 2. In
A, either PBS, plasma fibronectin (+Fn;
solid bar = 40 nM), monomeric RGD peptides
(+RGD; solid bar = 80 nM,
hatched bar = 80 µM), or polymeric RGD
peptides (Poly-RGD; solid bar = 5.7 nM; hatched bar = 5.7 µM)
were added to the cell/collagen mixture. Protein concentrations were
adjusted to reflect either equal molar ratios of RGD repeats
(solid bars) or a 1000-fold excess versus 40 nM fibronectin (hatched bars). In B,
20 nM of untreated fibronectin ( ; +Fn),
fibronectin (20 nM) pretreated with 62.5 µM
III-1C ( ; +Fn/III-1C), III-1C ( ; +III-1C),
or an equal volume of PBS ( ; Fn) were added to
cell/collagen mixtures. Collagen gels were cast and processed as
indicated in the legend to Fig. 2. Data are presented as a percentage
of the weight of gels not containing cells ± S.E. *, different
from the +Fn group (p < 0.01); #, different from the
+Fn group (p < 0.05).
|
|
Incubation of soluble fibronectin with a fragment of fibronectin's
III-1 module (III-1C), has been shown to trigger the formation of high
molecular mass multimers, termed superfibronectin (8). To determine
whether the interaction of cells with this prepolymerized form of
fibronectin could accelerate fibronectin-mediated collagen gel
contraction, cells were incubated for various amounts of time with
either soluble fibronectin or fibronectin that had been pretreated with
III-1C (8). As shown in Fig. 8B, incubation of cells with prepolymerized fibronectin did not accelerate collagen gel contraction versus untreated fibronectin. Moreover, addition of
prepolymerized fibronectin to collagen-imbedded cells decreased the
extent of collagen gel contraction compared with cells incubated with
untreated fibronectin (Fig. 8B). The ability of fibronectin
polymerization inhibitors to block the contractile response of cells to
fibronectin (Fig. 6), coupled with the inability of either monovalent
fragments (Figs. 4 and 8A), polymeric RGD (Fig.
8A), or prepolymerized fibronectin (Fig. 8B) to
stimulate cell contraction, suggests that the process of fibronectin
polymerization may be critical in triggering cytoskeletal tension
generation within collagen matrices.
Effect of Anti-integrin Antibodies on Fibronectin-mediated Collagen
Gel Contraction--
Cell-mediated contraction of collagen gels has
been shown to be dependent on 1 1 (22)
and/or 2 1 integrin ligation (23, 24).
Fibronectin polymerization by fibroblasts is mediated primarily by the
5 1 integrin (44, 49). In the absence of
5, other integrins, including
v-containing integrins, can promote fibronectin polymerization (44, 54, 55). In addition, recent studies suggest a role
for 5 1 integrin-fibronectin interactions
in enhancing clot retraction (56). To determine the relative
contributions of various integrin receptors to the fibronectin-mediated
stimulation of cell contractility, adhesion-blocking anti-integrin
antibodies were tested for their ability to inhibit fibronectin-induced
collagen gel contraction. As expected, the addition of an
anti- 1 integrin subunit antibody completely inhibited
collagen gel contraction of fibronectin-treated cells (Fig.
9). Addition of 10 µg/ml
anti- 5 antibodies alone or in combination with
anti- v antibodies resulted in a small but significant
reduction in fibronectin-induced contraction (Fig. 9). No further
inhibition of the fibronectin contraction response was observed when
the anti- 5 and anti- v antibody
concentrations were increased to 25 µg/ml (data not shown). In the
presence of fibronectin, addition of a combination of
anti- 1 and anti- 2 antibodies had only a
slight inhibitory effect on collagen gel contraction. Addition of
anti- 5 and anti- v antibodies to
1/ 2 integrin-blocked cells further
reduced collagen gel contraction to levels similar to those
observed in the absence of fibronectin (Fig. 9). Incubation of
cells with isotype-matched IgM or IgG antibodies did not alter
fibronectin-induced gel contraction (Fig. 9). These data indicate that
collagen- and fibronectin-integrin receptors act synergistically to
mediate fibronectin-induced collagen fibril contraction. Furthermore,
these data suggest that, in the presence of collagen-integrin
receptor blockade, fibronectin-integrin receptors can mediate
fibronectin-stimulated collagen gel contraction.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 9.
Effect of anti-integrin antibodies on
fibronectin-induced collagen gel contraction. Fibronectin-null
cells were imbedded into collagen gels as indicated in the legend to
Fig. 2 in the absence (+0) or presence of 40 nM
plasma fibronectin (+Fn). 30 min prior to imbedding, some
cells were incubated with 10 µg/ml each of various anti-integrin
antibodies or isotype-matched controls. Collagen gels were cast and
processed as indicated in the legend to Fig. 2. Data are presented as a
percentage of the weight of gels not containing cells ± S.E. *,
different from the +Fn group (p < 0.01).
|
|
Role of Fibronectin's Gelatin-binding Domain in
Fibronectin-induced Collagen Gel Contraction--
Neither
5 1 nor v 1
integrins bind directly to collagen (49). However, binding interactions
between fibronectin and either individual collagen fibrils (types I,
II, III, and IV) or denatured type I collagen have been demonstrated
in vitro (57, 58). The binding site for gelatin has been
localized to a 40-kDa domain in the amino-terminal region of
fibronectin (Fig. 1) (59). To determine whether the gelatin-binding
domain of fibronectin plays a role in fibronectin-mediated collagen gel
contraction, fibronectin-null cells were imbedded in
fibronectin-containing collagen gels in the absence and presence of
various concentrations of either an anti-gelatin-binding domain
monoclonal antibody or a control monoclonal antibody that recognizes an
epitope within the III-5 module of fibronectin (IST-5) (60). As
demonstrated in Fig. 10, addition of
anti-gelatin-binding domain antibodies resulted in a
dose-dependent inhibition of fibronectin-induced collagen
gel contraction. In contrast, addition of the anti-III-5 monoclonal
antibody had no effect on fibronectin-induced contraction (Fig. 10).
These data indicate that the gelatin-binding domain of fibronectin
plays a role in mediating fibronectin-stimulated contraction. The
anti-gelatin-binding domain antibody also inhibits fibronectin binding
to gelatin, as assessed by enzyme-linked immunoassay (D.C. Hocking,
unpublished observation). Thus, it is possible that fibronectin-binding
integrins mediate collagen gel contraction through the formation of a
tri-molecular complex in which integrin-bound fibronectin interacts
with collagen via the gelatin-binding domain of fibronectin.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 10.
Role of fibronectin's gelatin-binding
domain in collagen gel contraction. Fibronectin-null cells were
imbedded in collagen gels as indicated in the legend to Fig. 2 in the
absence ( ) or presence (+) of 40 nM
plasma fibronectin (Fn). At the time of imbedding,
increasing concentrations of antibodies directed against either the
gelatin binding domain (GBD) or the III-5 domain
(IST-5; 50 µg/ml) of fibronectin were added to the gels.
Collagen gels were cast and processed as indicated in the legend to
Fig. 2. Data are presented as a percentage of the weight of gels not
containing cells ± S.E.
|
|
Effect of Pertussis Toxin and C3 Exotransferase Treatment on
Fibronectin-mediated Gel Contraction--
To begin characterizing the
intracellular signals involved in fibronectin-mediated gel contraction,
fibronectin-null cells were pretreated with either the Gi
protein inhibitor, pertussis toxin (61) or with the Rho inhibitor, C3
exotransferase (62). The involvement of these pathways in the
contraction of floating collagen gels by human dermal fibroblasts has
been recently demonstrated (40). Pretreatment of fibronectin-null cells
with pertussis toxin completely inhibited the LPA-induced contraction
of floating collagen gels (Fig.
11A). In contrast, pertussis
toxin pretreatment had no significant effect on fibronectin-mediated
contraction (Fig. 11A), suggesting that the Gi
class of heterotrimeric G proteins is not involved in the contractile
response of cells to fibronectin. Inhibition of Rho activity by
pretreatment of cells with C3 exotransferase completely blocked the
fibronectin-mediated decrease in collagen gel weight (Fig.
11B); pretreatment of fibronectin-null cells with either
DMEM or the Lipofectin vehicle alone had no effect on
fibronectin-mediated contraction (Fig. 11B). These data
suggest that activation of the small G protein, Rho, is required for
the contraction of cells in response to fibronectin.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 11.
Effect of pertussis toxin or C3
exotransferase on fibronectin-induced contraction. In
A, fibronectin-null cell monolayers were incubated overnight
with 25 ng/ml pertussis toxin (+PTx, hatched
bars) or DMEM alone ( PTx, solid bars).
Cells were harvested and imbedded into collagen gels as indicated in
the legend to Fig. 2, in the absence (+0, +LPA)
or presence of 40 nM fibronectin (+Fn). Gels
were allowed to polymerize at 37 °C for 1 h after which time
either serum-free media (+0, +Fn) or serum-free
media containing 20 µg/ml LPA (+LPA) was added to the
wells. Gels were incubated an additional 20 h at 37 °C and then
removed and weighed. In B, cell monolayers were incubated
overnight with either 2 µg/ml C3 exotransferase plus Lipofectin
(hatched bars), Lipofectin alone (open bars), or
DMEM (solid bars). Cells were harvested and imbedded into
collagen gels, in the absence (+PBS) or presence of 40 nM fibronectin (+Fn). Gels were allowed to
polymerize at 37 °C for 1 h after which time either serum-free
media was added to wells. Gels were incubated an additional 6 h at
37 °C and then removed and weighed. Data are presented as a
percentage of the weight of gels not containing cells ± S.E.
|
|
Fibronectin Polymerization Induces Actin Cytoskeleton
Rearrangement--
During collagen gel contraction, fibroblasts
imbedded in three-dimensional, floating collagen gels progress from a
round to a spread phenotype (63). As cells spread, tractional forces generated from cellular extensions are thought to be the primary mechanism by which contraction of collagen fibrils occurs (64). To
correlate fibronectin-induced changes in mechanical tension generation
with changes in actin organization, cell spreading, and extension
formation, fibronectin-null cells were imbedded in collagen gels in the
absence and presence of 40 nM intact fibronectin or the
integrin-binding 120-kDa fibronectin fragment. To assess the role of
fibronectin polymerization on cell morphology and actin organization,
the anti-fibronectin III-1 antibody, 9D2, or the control, nonimmune IgG
was added to fibronectin-treated cells. Following a 20-h incubation,
cells imbedded in collagen gels were fixed and permeabilized, and actin
filaments were visualized with FITC-phalloidin. As demonstrated in Fig.
12, in the absence of fibronectin,
collagen-imbedded fibronectin-null cells remained round (Fig.
12A). Similarly, treatment of cells with the 120-kDa integrin-binding fibronectin fragment did not promote cell spreading (Fig. 12B). In contrast, treatment of cells with fibronectin
resulted in actin filament reorganization, cell spreading, and the
formation of cell extensions (Fig. 12, C and D).
These fibronectin-induced morphological changes were blocked by the
addition of the 9D2 mAb, which inhibits fibronectin polymerization (35)
(Fig. 12E). Addition of nonimmune mouse IgG had no effect on
cell spreading or extension formation of fibronectin-treated cells
(Fig. 12F). Similar results were observed following a 4-h
incubation (not shown). Taken together, these data indicate that actin
reorganization, cell spreading, and the formation of cellular
extensions within a collagen lattice are stimulated by fibronectin
polymerization.

View larger version (77K):
[in this window]
[in a new window]
|
Fig. 12.
Effect of fibronectin polymerization on
actin organization. Fibronectin-null cells were imbedded into
collagen gels in the absence (A) or presence of the
integrin-binding 120-kDa fibronectin fragment (B), intact
fibronectin (C and D), intact fibronectin plus 25 µg/ml 9D2 Fab' (E), or intact fibronectin plus 25 µg/ml
nonimmune mouse Fab' (F). Following a 20-h incubation, gels
were fixed with paraformaldehyde and permeabilized with acetone. Actin
was visualized by staining with FITC-phalloidin. Gels were mounted and
examined using an Olympus BX60 microscope equipped with epifluorescence
and photographed using a Spot digital camera. Data represent one of
three experiments performed.
|
|
 |
DISCUSSION |
In the present study, we have demonstrated that fibronectin
polymerization stimulates the spreading of fibronectin-null cells imbedded in collagen gels and triggers a significant increase in cell
contractility, as measured by collagen gel contraction. The increase in
cell contractility induced by fibronectin was dependent on integrin
ligation; however, ligation of integrin receptors by fibronectin
fragments was not sufficient to induce either tension generation or
cell spreading. Cell contractility could not be stimulated by treatment
of cells with either polyvalent RGD peptides or prepolymerized
fibronectin. Moreover, fibronectin-induced contractility was blocked by
agents that inhibit fibronectin polymerization, suggesting that the
process of fibronectin polymerization is critical in triggering
cytoskeletal tension generation. Fibronectin-induced contractility was
inhibited by pretreatment of cells with C3 exotransferase but not by
pretreatment with pertussis toxin, suggesting a role for RhoA in the
contractile response of cells to fibronectin polymerization. These data
are the first to demonstrate that Rho-mediated cell contractility may
be regulated by the process of fibronectin polymerization and suggest a
novel mechanism by which extracellular matrix fibronectin regulates
cytoskeletal organization and cell function.
Our data suggest that fibronectin-binding integrins may mediate native
collagen fibril reorganization through an interaction of the
gelatin-binding domain of integrin-bound fibronectin with collagen
fibrils. Competition binding assays indicate that the affinity of
fibronectin for native collagen fibrils is approximately 10- to
100-fold lower than that of gelatin (57), prompting the suggestion that
fibronectin may not bind to native collagen under physiological
conditions (65). However, previous studies have demonstrated
colocalization of fibronectin and collagen fibers in cultured
fibroblasts (66-68). In addition, microscopic analyses of cutaneous
wounds indicate that fibronectin fibrils are associated with type I
(69) and type III (68) collagen fibrils. Furthermore, inhibition of
fibronectin polymerization by anti-fibronectin antibodies inhibits
collagen deposition by lung fibroblasts (70). These data, together with
the data presented here, suggest that the interaction of fibronectin
with the cell surface may increase the affinity of fibronectin for
native collagen. Previous studies have identified
conformation-dependent binding sites within fibronectin (36, 39) that may be exposed by changes in cell contractility (71).
Further studies will be required to explore the possibility that
fibronectin polymerization or cell contraction induces a conformational
change within the gelatin-binding domain of fibronectin to enhance its
collagen-binding activity.
The interaction of cells with fibronectin via cell surface integrin
receptors generates a series of complex signaling events that serve to
regulate many aspects of cell behavior, including growth,
differentiation, adhesion, and motility (44, 49). Data presented in
this study extend these observation by suggesting that the
polymerization of an insoluble fibronectin matrix provides a distinct
control mechanism to tightly couple the organization of the actin
cytoskeleton to the organization of the extracellular environment.
Fibronectin deposition may be rapidly up- and down-regulated by such
factors as protein kinase C, cyclic AMP, and LPA (14-17). Activators
of protein kinase C, which affect both stress fiber and focal contact
formation (72), enhance fibronectin matrix assembly (17). Conversely,
increasing intracellular cAMP levels, which disrupt actin stress fibers
and cause cell retraction (73), inhibits matrix assembly (14). In
addition, studies have demonstrated decreased fibronectin deposition
upon disruption of the actin cytoskeleton with cytochalasin D (74). In
the present study, cell contractility was inhibited by agents
previously shown to inhibit fibronectin polymerization. Moreover, cell
contractility could not be stimulated by treatment of cells with either
monovalent fibronectin fragments, polyvalent RGD peptides, or
prepolymerized fibronectin, suggesting that the process of fibronectin
polymerization is critical in triggering cytoskeletal tension
generation. Taken together, these studies suggest that a dynamic,
reciprocal relationship exists between fibronectin polymerization,
cytoskeletal organization, and the contractile state of the cell that
may serve to regulate cell behavior.
Previous studies have defined a role for Rho-mediated contractility in
fibronectin polymerization (16, 71, 75). Increasing Rho-stimulated
contraction through treatment of cells with either LPA (16, 71) or
nocodazole (75) or by microinjection of recombinant, constitutively
active Rho (71) results in enhanced fibronectin deposition. In the
present study, cell contractility induced by fibronectin polymerization
was inhibited by pretreatment of cells with the Rho inhibitor, C3
exotransferase. In addition, spreading and extension formation by cells
imbedded in collagen gels were dependent on fibronectin polymerization,
and could not be stimulated by integrin-binding fragments of
fibronectin. These data suggest that fibronectin polymerization
triggers integrin-mediated cytoskeletal reorganization and enhances
cell contractility through a mechanism involving the activation of
RhoA. Recent studies have demonstrated that disruption of preformed
extracellular matrices by treatment with the III-1C fragment of
fibronectin blocks the ability of LPA to stimulate stress fiber
formation (6). In addition, other studies suggest that actin stress
fiber formation follows fibronectin matrix assembly (6) and is
dependent on the three-dimensional structure of extracellular
fibronectin (9). Taken together, these data suggest that fibronectin
polymerization and deposition into the extracellular matrix stimulates
Rho activation and subsequent actin cytoskeleton organization.
Moreover, these data suggest that Rho activity may be sustained or
potentiated by the continued deposition or remodeling of a fibronectin matrix.
One of the histological hallmarks of chronic inflammatory diseases,
including interstitial pulmonary fibrosis and asthma, is an excessive
and/or inappropriate deposition of extracellular matrix molecules that
is thought to arise as a consequence of unresolved wound repair (76,
77). In the present study, we have used a well-characterized model of
wound contraction (19-21, 40, 78, 79) to demonstrated that fibronectin
stimulates the contraction of collagen matrices by a mechanism that
requires both integrin ligation and fibronectin polymerization. These
studies suggest that in normal wound healing, remodeling of the
collagen matrix may be regulated in part, by the rate and extent of
fibronectin polymerization into the extracellular matrix. In chronic
inflammatory diseases, excessive fibronectin deposition into the
extracellular matrix may contribute to the pathogenesis of the disease
by triggering abnormal tissue remodeling through changes in the
organization and contraction of collagen fibrils.
In summary, our data indicate that fibronectin enhances cell
contractility and alters cytoskeletal organization by a mechanism that
is dependent on fibronectin polymerization. Other studies have shown
that cytoskeletal assembly and stiffness increase in proportion to the
stress applied to integrin receptors (10, 11). In addition, cell
spreading, migration (12), and cytoskeletal assembly (13) are regulated
by the mechanical stiffness of the adhesive substrate. Therefore, it is
possible that fibronectin polymerization promotes cell contractility
through local alterations in cytoskeletal organization that are
mediated in part by changes in the rigidity of the insoluble
fibronectin matrix. Additionally, cell-mediated fibronectin
polymerization may trigger conformational changes within the
fibronectin molecule (71, 80) resulting in the exposure of neoepitopes
that have unique affects on actin cytoskeletal organization. As such,
future studies aimed at elucidating the precise mechanism by which
fibronectin polymerization affects cell contractility will provide
important insight into the extracellular factors that control
cytoskeletal organization and, in addition, may suggest novel
approaches for the development of therapeutic strategies aimed at
preventing abnormal tissue remodeling following injury.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Deane Mosher for providing the
9D2 hybridoma cells, Dr. Jean Schwarzbauer for providing the
fibronectin cDNAs, and Michelle Arquette for help with purifying
the recombinant fibronectins.
 |
FOOTNOTES |
*
This work was supported by Grants HL60181 (to D. H.),
HL 64074 (to D. H.), HL50549 (to J. S.), and HL03971 (to
J. S.) of the National Institutes of Health.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Department of
Pharmacology and Physiology, University of Rochester Medical Center, 601 Elmwood Ave., Box 711, Rochester, NY 14642. Tel.: 716-273-1770; Fax: 716-244-9283; E-mail: denise_hocking@urmc.rochester.edu.
Supported by NIH Predoctoral Training Grant T32-HL07194.
 |
ABBREVIATIONS |
The abbreviations used are:
PAGE, polyacrylamide
gel electrophoresis;
DMEM, Dulbecco's modified Eagle's media;
BSA, bovine serum albumin;
PCR, polymerase chain reaction;
LPA, 1-oleoyl
lysophosphatidic acid;
mAb, monoclonal antibody;
FITC, fluorescein
isothiocyanate.
 |
REFERENCES |
| 1.
|
Hynes, R. O.
(1990)
Fibronectins
, Springer-Verlag, New York
|
| 2.
|
Magnusson, M.,
and Mosher, D. F.
(1998)
Arterioscler. Thromb. Vasc. Biol.
18,
1363-1370[Free Full Text]
|
| 3.
|
Chicurel, M. E.,
Chen, C. S.,
and Ingber, D. E.
(1998)
Curr. Opin. Cell Biol.
10,
232-239[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Sottile, J.,
Hocking, D. C.,
and Swiatek, P. J.
(1998)
J. Cell Sci.
111,
2933-2943[Abstract]
|
| 5.
|
Sechler, J. L.,
and Schwarzbauer, J. E.
(1998)
J. Biol. Chem.
273,
25533-25536[Abstract/Free Full Text]
|
| 6.
|
Bourdoulous, S.,
Orend, G.,
MacKenna, D. A.,
Pasqualini, R.,
and Ruoslahti, E.
(1998)
J. Cell Biol.
143,
267-276[Abstract/Free Full Text]
|
| 7.
|
Mercurius, K. O.,
and Morla, A. O.
(1998)
Circ. Res.
82,
548-556[Abstract/Free Full Text]
|
| 8.
|
Morla, A.,
Zhang, Z.,
and Ruoslahti, E.
(1994)
Nature
367,
193-196[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Sechler, J. L.,
and Schwarzbauer, J. E.
(1997)
Cell Adhes. Commun.
4,
413-424[Medline]
[Order article via Infotrieve]
|
| 10.
|
Choquet, D.,
Felsenfeld, D. P.,
and Sheetz, M. P.
(1997)
Cell
88,
39-48[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Wang, N.,
Butler, J. P.,
and Ingber, D. E.
(1993)
Science
260,
1124-1127[Abstract/Free Full Text]
|
| 12.
|
Pelham, R. J., Jr.,
and Wang, Y.-L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13661-13665[Abstract/Free Full Text]
|
| 13.
|
Tomasek, J. J.,
Haaksma, C. J.,
Eddy, R. J.,
and Vaughan, M. B.
(1992)
Anat. Rec.
232,
359-368[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Allen-Hoffman, L. B.,
and Mosher, D. F.
(1987)
J. Biol. Chem.
262,
14361-14365[Abstract/Free Full Text]
|
| 15.
|
Checovich, W.,
and Mosher, D.
(1993)
Arterioscler. Thromb.
13,
1662-1667[Abstract/Free Full Text]
|
| 16.
|
Zhang, Q.,
Checovich, W. J.,
Peters, D. M.,
Albrecht, R. M.,
and Mosher, D. F.
(1994)
J. Cell Biol.
127,
1447-1459[Abstract/Free Full Text]
|
| 17.
|
Somers, C.,
and Mosher, D. F.
(1993)
J. Biol. Chem.
268,
22277-22280[Abstract/Free Full Text]
|
| 18.
|
Lee, K.-M.,
Tsai, K. Y.,
Wang, N.,
and Ingber, D. E.
(1998)
Am. J. Physiol.
274,
H76-H82
|
| 19.
|
Bell, E.,
Erhlich, H. P.,
Buttle, J.,
and Nakatsuji, T.
(1981)
Science
211,
1052-1054[Abstract/Free Full Text]
|
| 20.
|
Bellows, C. G.,
Melcher, A. H.,
and Aubin, J. E.
(1982)
J. Cell Sci.
58,
125-138[Abstract]
|
| 21.
|
Stopak, D.,
and Harris, A. K.
(1982)
Dev. Biol.
90,
383-398[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Gotwals, P. J.,
Chi-Rosso, G.,
Lindner, V.,
Yang, J.,
Ling, L.,
Fawall, S. E.,
and Koteliansky, V. E.
(1996)
J. Clin. Invest.
97,
2469-2477[Medline]
[Order article via Infotrieve]
|
| 23.
|
Schiro, J. A.,
Chan, B. M. C.,
Roswit, W. T.,
Kassner, P. D.,
Pentland, A. P.,
Hemler, M. E.,
Eisen, A. Z.,
and Kupper, T. S.
(1991)
Cell
67,
403-410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Klein, C. E.,
Dressel, D.,
Steinmayer, T.,
Mauch, C.,
Eckes, B.,
Kreig, T.,
Bankert, R. B.,
and Weber, L.
(1991)
J. Cell Biol.
115,
1427-1436[Abstract/Free Full Text]
|
| 25.
|
Yatohgo, T.,
Izumi, M.,
Kashiwagi, H.,
and Hayashi, M.
(1988)
Cell Struct. Funct.
13,
281-292[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Miekka, S. I.,
Ingham, K. C.,
and Menache, D.
(1982)
Thromb. Res.
27,
1-14[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
McKeown-Longo, P. J.,
and Mosher, D. F.
(1985)
J. Cell Biol.
100,
364-374[Abstract/Free Full Text]
|
| 28.
|
Balian, G.,
Click, E. M.,
and Bornstein, P.
(1980)
J. Biol. Chem.
255,
3234-3236[Abstract/Free Full Text]
|
| 29.
|
McDonald, J. A.,
and Kelley, D. G.
(1980)
J. Biol. Chem.
255,
8848-8858[Abstract/Free Full Text]
|
| 30.
|
Pierschbacher, M. D.,
Hayman, E. G.,
and Ruoslahti, E.
(1981)
Cell
26,
259-267[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 32.
|
Petersen, T. E.,
Skorstengaard, K.,
and Vibe-Pedersen, K.
(1989)
in
Fibronectin
(Mosher, D. F., ed)
, pp. 1-24, Academic Press, New York
|
| 33.
|
Schwarzbauer, J.
(1991)
J. Cell Biol.
113,
1463-1473[Abstract/Free Full Text]
|
| 34.
|
Sottile, J.,
and Wiley, S.
(1994)
J. Biol. Chem.
269,
17192-17198[Abstract/Free Full Text]
|
| 35.
|
Chernousov, M. A.,
Fogerty, F. J.,
Koteliansky, V. E.,
and Mosher, D. F.
(1991)
J. Biol. Chem.
266,
10851-10858[Abstract/Free Full Text]
|
| 36.
|
Hocking, D. C.,
Smith, R. K.,
and McKeown-Longo, P. J.
(1996)
J. Cell Biol.
133,
431-444[Abstract/Free Full Text]
|
| 37.
|
Rodt, S. A.,
Reed, R. K.,
Ljungstrom, M.,
Gustafsson, T. O.,
and Rubin, K.
(1994)
Circ. Res.
75,
942-948[Abstract/Free Full Text]
|
| 38.
|
Tingstrom, A.,
Heldin, C.-H.,
and Rubin, K.
(1992)
J. Cell Sci.
102,
315-322[Abstract/Free Full Text]
|
| 39.
|
Hocking, D. C.,
Sottile, J.,
and McKeown-Longo, P. J.
(1994)
J. Biol. Chem.
269,
19183-19191[Abstract/Free Full Text]
|
| 40.
|
Grinnell, F.,
Ho, C.-H.,
Lin, Y.-C.,
and Skuta, G.
(1999)
J. Biol. Chem.
274,
918-923[Abstract/Free Full Text]
|
| 41.
|
Kreisberg, J. I.,
Ghosh-Choudhury, N.,
Radnick, R. A.,
and Schwartz, M. A.
(1997)
Am. J. Physiol.
273,
F283-F288[Abstract/Free Full Text]
|
| 42.
|
Small, J. V.,
and Celis, J. E.
(1978)
Eur. J. Cell Biol.
16,
308-325
|
| 43.
|
Miyamoto, S.,
Teramoto, H.,
Coso, O. A.,
Gutkind, J. S.,
Burbelo, P. D.,
Akiyama, S. K.,
and Yamada, K. M.
(1995)
J. Cell Biol.
131,
791-805[Abstract/Free Full Text]
|
| 44.
|
Schwartz, M.,
Schaller, M. D.,
and Ginsberg, M. H.
(1995)
Annu. Rev. Cell Biol.
11,
549-599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Burridge, K.,
and Chrzanowska-Wodnicka, M.
(1996)
Annu. Rev. Cell Dev. Biol.
12,
463-519[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Woods, A.,
Couchman, J. R.,
Johansson, S.,
and Hook, M.
(1986)
EMBO J.
5,
665-670[Medline]
[Order article via Infotrieve]
|
| 47.
|
Bloom, L.,
Ingham, K. C.,
and Hynes, R. O.
(1999)
Mol. Biol. Cell
10,
1521-1536[Abstract/Free Full Text]
|
| 48.
|
McKeown-Longo, P. J.,
and Mosher, D. F.
(1983)
J. Cell Biol.
97,
466-472[Abstract/Free Full Text]
|
| 49.
|
Hynes, R. O.
(1992)
Cell
69,
11-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Quade, B. J.,
and McDonald, J. A.
(1988)
J. Biol. Chem.
263,
19602-19609[Abstract/Free Full Text]
|
| 51.
|
Staatz, W. D.,
Fok, K. F.,
Zutter, M. M.,
Adams, S. P.,
Rodriguez, B. A.,
and Santoro, S. A.
(1991)
J. Biol. Chem.
266,
7363-7367[Abstract/Free Full Text]
|
| 52.
|
Gullberg, D.,
Gehlsen, K. R.,
Turner, D. C.,
Ahlen, K.,
Zijenah, L. S.,
Barnes, M. J.,
and Rubin, K.
(1992)
EMBO J.
11,
3865-3873[Medline]
[Order article via Infotrieve]
|
| 53.
|
Stupack, D. G.,
Li, E.,
Silletti, S. A.,
Kehler, J. A.,
Geahlen, R. L.,
Hahn, K.,
Nemerow, G. R.,
and Cherish, D. A.
(1999)
J. Cell Biol.
144,
777-787[Abstract/Free Full Text]
|
| 54.
|
Yang, J. T.,
and Hynes, R. O.
(1996)
Mol. Biol. Cell
7,
1737-1748[Abstract]
|
| 55.
|
Wu, C.,
Hughes, P. E.,
Ginsberg, M. H.,
and McDonald, J. A.
(1996)
Cell Adhes. Commun.
4,
149-158[Medline]
[Order article via Infotrieve]
|
| 56.
|
Corbett, S. A.,
and Schwarzbauer, J. E.
(1999)
J. Biol. Chem.
274,
20943-20948[Abstract/Free Full Text]
|
| 57.
|
Engvall, E.,
Ruoslahti, E.,
and Miller, E. J.
(1978)
J. Exp. Med.
147,
1584-1595[Abstract/Free Full Text]
|
| 58.
|
Engvall, E.,
and Ruoslahti, E.
(1977)
Int. J. Cancer.
20,
1-5[Medline]
[Order article via Infotrieve]
|
| 59.
|
Owens, R. J.,
and Baralle, F. E.
(1986)
EMBO J.
5,
2825-2830[Medline]
[Order article via Infotrieve]
|
| 60.
|
Zardi, L.,
Carnemolla, B.,
Balza, E.,
Borsi, L.,
Castellani, P.,
Rocco, M.,
and Siri, A.
(1985)
Eur. J. Biochem.
146,
571-579[Medline]
[Order article via Infotrieve]
|
| 61.
|
Suchard, S. J.,
and Mansfield, P. J.
(1996)
J. Cell. Physiol.
168,
217-227[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Narumiya, S.,
Sekine, A.,
and Fujiwara, M.
(1988)
J. Biol. Chem.
263,
17255-17257[Abstract/Free Full Text]
|
| 63.
|
Ehrlich, H. P.,
and Rajaratnam, J. B.
(1990)
Tissue Cell
22,
407-417[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Harris, A. K.,
Stopak, D.,
and Wild, P.
(1981)
Nature
290,
249-251[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Hynes, R. O.
(1990)
in
Fibronectins
(Hynes, R. O., ed)
, pp. 84-93, Springer-Verlag, New York
|
| 66.
|
Little, C. D.,
and Chen, W.-T.
(1982)
J. Cell Sci.
55,
35-50[Abstract]
|
| 67.
|
Furcht, L. T.,
Smith, D.,
Wendelschafer-Crabb, G.,
Mosher, D. F.,
and Foidart, J. M.
(1980)
J. Histochem. Cytochem.
28,
1319-1333[Abstract]
|
| 68.
|
Vaheri, A.,
Kurkinen, M.,
Lehto, V.-P.,
Linder, E.,
and Timpl, R.
(1978)
Proc. Natl. Acad. Sci. U. S. A.
75,
4944-4948[Abstract/Free Full Text]
|
| 69.
|
Welch, M. P.,
Odland, G. F.,
and Clark, R. A. F.
(1990)
J. Cell Biol.
110,
133-145[Abstract/Free Full Text]
|
| 70.
|
McDonald, J. A.,
Kelley, D. G.,
and Broekelmann, T. J.
(1982)
J. Cell Biol.
92,
485-492[Abstract/Free Full Text]
|
| 71.
|
Zhong, C.,
Chrzanowska-Wodnicka, M.,
Brown, J.,
Shaub, A.,
Belkin, A. M.,
and Burridge, K.
(1998)
J. Cell Biol.
141,
539-551[Abstract/Free Full Text]
|
| 72.
|
Woods, A.,
and Couchman, J. R.
(1992)
J. Cell Sci.
101,
277-290[Abstract/Free Full Text]
|
| 73.
|
Lamb, N. J. C.,
Fernandez, A.,
Conti, M. A.,
Adelstein, R.,
Glass, D. B.,
Welch, W. J.,
and Feramisco, J. R.
(1988)
J. Cell Biol.
106,
1955-1971[Abstract/Free Full Text]
|
| 74.
|
Wu, C.,
Keivens, V. M.,
O'Toole, T. E.,
McDonald, J. A.,
and Ginsberg, M. H.
(1995)
Cell
83,
715-724[CrossRef][Medline]
[Order article via Infotrieve]
|
| 75.
|
Zhang, Q.,
Magnusson, M. K.,
and Mosher, D. F.
(1997)
Mol. Biol. Cell
8,
1415-1425[Abstract]
|
| 76.
|
Bousquet, J.,
Chanez, P.,
Lacoste, J. Y.,
White, R.,
Vic, P.,
Godard, P.,
and Michel, F. B.
(1992)
Allergy
47,
3-11[Medline]
[Order article via Infotrieve]
|
| 77.
|
Clark, R. A. F.
(1995)
in
The Molecular and Cellular Biology of Wound Repair
(Clark, R. A. F., ed)
, pp. 3-50, Plenum Press, New York
|
| 78.
|
Guidry, C.,
and Grinnell, F.
(1985)
J. Cell Sci.
79,
67-81[Abstract]
|
| 79.
|
Grinnel, F.,
and Lamke, C.
(1984)
J. Cell Sci.
66,
51-63[Abstract]
|
| 80.
|
Peters, D. M. P,
Chen, Y.,
Zardi, L.,
and Brummel, S.
(1998)
Microsc. Microanal.
4,
385-396[Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Z. Sun, L. A. Martinez-Lemus, M. A. Hill, and G. A. Meininger
Extracellular matrix-specific focal adhesions in vascular smooth muscle produce mechanically active adhesion sites
Am J Physiol Cell Physiol,
July 1, 2008;
295(1):
C268 - C278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zhou, R. G. Rowe, N. Hiraoka, J. P. George, D. Wirtz, D. F. Mosher, I. Virtanen, M. A. Chernousov, and S. J. Weiss
Fibronectin fibrillogenesis regulates three-dimensional neovessel formation
Genes & Dev.,
May 1, 2008;
22(9):
1231 - 1243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Hocking, P. A. Titus, R. Sumagin, and I. H. Sarelius
Extracellular Matrix Fibronectin Mechanically Couples Skeletal Muscle Contraction With Local Vasodilation
Circ. Res.,
February 15, 2008;
102(3):
372 - 379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sottile, F. Shi, I. Rublyevska, H.-Y. Chiang, J. Lust, and J. Chandler
Fibronectin-dependent collagen I deposition modulates the cell response to fibronectin
Am J Physiol Cell Physiol,
December 1, 2007;
293(6):
C1934 - C1946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Gui, K. Wojciechowski, C. D. Gildner, H. Nedelkovska, and D. C. Hocking
Identification of the Heparin-binding Determinants within Fibronectin Repeat III1: ROLE IN CELL SPREADING AND GROWTH
J. Biol. Chem.,
November 17, 2006;
281(46):
34816 - 34825.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sottile and J. Chandler
Fibronectin Matrix Turnover Occurs through a Caveolin-1-dependent Process
Mol. Biol. Cell,
February 1, 2005;
16(2):
757 - 768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Gildner, A. L. Lerner, and D. C. Hocking
Fibronectin matrix polymerization increases tensile strength of model tissue
Am J Physiol Heart Circ Physiol,
July 1, 2004;
287(1):
H46 - H53.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. R. Polte, G. S. Eichler, N. Wang, and D. E. Ingber
Extracellular matrix controls myosin light chain phosphorylation and cell contractility through modulation of cell shape and cytoskeletal prestress
Am J Physiol Cell Physiol,
March 1, 2004;
286(3):
C518 - C528.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Kazi, S. Lotfi, E. A. Goncharova, O. Tliba, Y. Amrani, V. P. Krymskaya, and A. L. Lazaar
Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent
Am J Physiol Lung Cell Mol Physiol,
March 1, 2004;
286(3):
L539 - L545.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. E. Robinson, R. A. Foty, and S. A. Corbett
Fibronectin Matrix Assembly Regulates {alpha}5{beta}1-mediated Cell Cohesion
Mol. Biol. Cell,
March 1, 2004;
15(3):
973 - 981.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Jarvelainen, R. B. Vernon, M. D. Gooden, A. Francki, S. Lara, P. Y. Johnson, M. G. Kinsella, E. H. Sage, and T. N. Wight
Overexpression of Decorin by Rat Arterial Smooth Muscle Cells Enhances Contraction of Type I Collagen In Vitro
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2004;
24(1):
67 - 72.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Klein, M. Zheng, A. Ambesi, L. Van De Water, and P. J. McKeown-Longo
Stimulation of extracellular matrix remodeling by the first type III repeat in fibronectin
J. Cell Sci.,
November 15, 2003;
116(22):
4663 - 4674.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. M. Verderio, D. Telci, A. Okoye, G. Melino, and M. Griffin
A Novel RGD-independent Cell Adhesion Pathway Mediated by Fibronectin-bound Tissue Transglutaminase Rescues Cells from Anoikis
J. Biol. Chem.,
October 24, 2003;
278(43):
42604 - 42614.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Hocking and C. H. Chang
Fibronectin matrix polymerization regulates small airway epithelial cell migration
Am J Physiol Lung Cell Mol Physiol,
July 1, 2003;
285(1):
L169 - L179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Shiokawa, M. Iwashita, Y. Akimoto, S. Nagamatsu, K. Sakai, H. Hanashi, M. Kabir-Salmani, Y. Nakamura, M. Uehata, and Y. Yoshimura
Small Guanosine Triphospatase RhoA and Rho-Associated Kinase as Regulators of Trophoblast Migration
J. Clin. Endocrinol. Metab.,
December 1, 2002;
87(12):
5808 - 5816.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Hocking
Fibronectin Matrix Deposition and Cell Contractility: Implications for Airway Remodeling in Asthma
Chest,
December 1, 2002;
122(6_suppl):
275S - 278S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Tamariz and F. Grinnell
Modulation of Fibroblast Morphology and Adhesion during Collagen Matrix Remodeling
Mol. Biol. Cell,
November 1, 2002;
13(11):
3915 - 3929.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sottile and D. C. Hocking
Fibronectin Polymerization Regulates the Composition and Stability of Extracellular Matrix Fibrils and Cell-Matrix Adhesions
Mol. Biol. Cell,
October 1, 2002;
13(10):
3546 - 3559.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Midwood and J. E. Schwarzbauer
Tenascin-C Modulates Matrix Contraction via Focal Adhesion Kinase- and Rho-mediated Signaling Pathways
Mol. Biol. Cell,
October 1, 2002;
13(10):
3601 - 3613.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Hocking and K. Kowalski
A cryptic fragment from fibronectin's III1 module localizes to lipid rafts and stimulates cell growth and contractility
J. Cell Biol.,
July 8, 2002;
158(1):
175 - 184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Lim, I. Han, H. J. Kwon, and E.-S. Oh
Trichostatin A-induced Detransformation Correlates with Decreased Focal Adhesion Kinase Phosphorylation at Tyrosine 861 in ras-transformed Fibroblasts
J. Biol. Chem.,
April 5, 2002;
277(15):
12735 - 12740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Pereira, B. J. Rybarczyk, T. M. Odrljin, D. C. Hocking, J. Sottile, and P. J. Simpson-Haidaris
The incorporation of fibrinogen into extracellular matrix is dependent on active assembly of a fibronectin matrix
J. Cell Sci.,
January 2, 2002;
115(3):
609 - 617.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Filla, X. Liu, T. D. Nguyen, J. R. Polansky, C. R. Brandt, P. L. Kaufman, and D. M. Peters
In Vitro Localization of TIGR/MYOC in Trabecular Meshwork Extracellular Matrix and Binding to Fibronectin
Invest. Ophthalmol. Vis. Sci.,
January 1, 2002;
43(1):
151 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Stupack, X. S. Puente, S. Boutsaboualoy, C. M. Storgard, and D. A. Cheresh
Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins
J. Cell Biol.,
October 29, 2001;
155(3):
459 - 470.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Burns, A. J. Thrasher, M. P. Blundell, L. Machesky, and G. E. Jones
Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and differentiation
Blood,
August 15, 2001;
98(4):
1142 - 1149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Sottile, D. Hocking, and K. Langenbach
Fibronectin polymerization stimulates cell growth by RGD-dependent and -independent mechanisms
J. Cell Sci.,
January 12, 2000;
113(23):
4287 - 4299.
[Abstract]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|